The Government Employees Medical Scheme (GEMS) has suspended its principal officer, Stan Moloabi, adding a new development to the challenges facing South Africa’s largest medical scheme serving public-sector employees and their dependants.
Moloabi confirmed his suspension on Tuesday morning but declined to discuss the reasons behind the board’s decision.
He said the terms attached to his suspension prevented him from providing further information, leaving the circumstances surrounding the move unclear.
More Than 2.4 Million Beneficiaries Affected
GEMS provides medical cover to more than 2.4 million beneficiaries, making developments within the scheme significant for a large number of public servants and their families.
The scheme has also been under pressure over the cost of contributions, with organised labour raising concerns about increases affecting members during 2026.
The latest leadership development comes against that backdrop, although there has been no indication that Moloabi’s suspension is directly connected to the contribution dispute.
Contribution Increase Triggered Union Pressure
GEMS faced sustained pressure from unions over its proposed contribution increases for 2026.
The scheme initially set the weighted average increase at 9.8% before reducing it to 9.5%, with the revised increase taking effect from April 1.
The contribution issue subsequently remained a contentious matter between the scheme and stakeholders representing public servants.
GEMS Tried to Reduce the Increase Again
On May 7, GEMS announced another adjustment, proposing to reduce the contribution increase to 7.5% from July 1.
However, that proposal did not ultimately proceed.
The Council for Medical Schemes vetoed the reduction, citing concerns that the move could threaten GEMS’s financial stability.
The decision added another layer of pressure to a scheme already dealing with concerns over affordability, member contributions and its long-term financial position.
Reason for Moloabi’s Suspension Remains Unknown
Despite confirming that he had been suspended, Moloabi has not disclosed why the GEMS board took the decision.
His refusal to elaborate means it is not yet clear whether the suspension relates to internal governance matters, financial issues, operational decisions or another matter.
GEMS had not immediately provided a comment on the development.
Until the scheme or its board provides further information, the reasons for the suspension remain unconfirmed.
Leadership Change Comes During a Difficult Period
The suspension places additional attention on the leadership of an organisation responsible for healthcare coverage for millions of beneficiaries.
GEMS has spent much of the past year navigating pressure over contribution increases while also having to balance affordability for members against the financial requirements of maintaining a sustainable medical scheme.
The Council for Medical Schemes’ intervention over the proposed 7.5% increase highlighted the tension between keeping contributions manageable and protecting the scheme’s financial health.
What’s Next?
The immediate focus will be on whether GEMS provides an explanation for Moloabi’s suspension and whether the board announces any interim arrangements for the principal officer position.
Further developments could also clarify whether the suspension has any connection to the scheme’s recent contribution and financial challenges.
For now, Moloabi remains bound by the conditions of his suspension and has indicated that he cannot comment further.
Summary
GEMS principal officer Stan Moloabi has confirmed that he has been suspended by the scheme’s board but has declined to discuss the reasons, citing the conditions of his suspension.
The development comes as GEMS continues to face scrutiny over contribution increases and financial sustainability.
The scheme initially proposed a 9.8% weighted average increase for 2026 before reducing it to 9.5%, and later sought to bring the increase down to 7.5%.
The Council for Medical Schemes subsequently vetoed the 7.5% proposal, warning that it could threaten GEMS’s financial stability.
With more than 2.4 million beneficiaries relying on the scheme, attention will now turn to the board’s next steps and any explanation for the suspension.
